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Abstract 
Side effects inherent to systemic beta-blockers make propranolol contraindicated in patients with certain 
cardiac and pulmonary conditions. Due to systemic absorption, topical beta-blockers such as timolol 
maleate, which are used as anti-glaucoma agents, have similar contraindications. The follow report 
describes an ocular hypertensive patient who was switched from timolol maleate to latanoprost because 
of a newly diagnosed possibility of mild COPD. The patient developed a bilateral hand tremor, which was 
previously blocked by systemic absorption of the topical beta-blocker. Included are classification, 
differential diagnosis and treatment of essential tremor, as well as a review of the mechanism of action 
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ABSTRACT: 
Side effects inherent to systemic beta-blockers make propranolol contraindicated in 
patients with certain cardiac and pulmonary conditions. Due to systemic absorption, topical 
beta-blockers such as timolol maleate, which are used as anti-glaucoma agents, have similar 
contraindications. 
The follow report describes an ocular hypertensive patient who was switched from 
timolol maleate to latanoprost because of a newly diagnosed possiblity of mild COPD. The 
patient developed a bilateral hand tremor, which was previously blocked by systemic absorption 
of the topical beta-blocker. Included are classification, differential diagnosis and treatment of 
essential tremor, as well as a review of the mechanism of action and contraindications of timolol 
maleate and latanoprost. 
KEYWORDS: 
Essential tremor, glaucoma, ocular hypertension, timolol maleate, latanoprost 
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INTRODUCTION: 
A CASE OF ESSENTIAL TREMOR 
MASKED BY THE TOPICAL 
BETA BLOCKER TIMOLOL MALEATE 
The introduction of new topical glaucoma medications such as latanoprost, with minimal 
systemic side effects or contraindications provides an alternative to traditional treatment with 
topical beta-blockers such as timolol maleate. Because topically applied ocular medications are 
absorbed systemically, the use of beta-blockers is contraindicated in patients with cardiac or 
pulmonary conditions. In addition, eyecare professionals must continually evaluate their patients 
using these medications for systemic side effects because it has been shown that as many as 40% 
of patients treated with topical timolol maleate develop a decrease in pulmonary function. 
Although changing from one medication to another is indicated whenever a patient 
develops cardiac or respiratory difficulties, this alteration in medication can have surprising 
results. In this case report, an ocular hypertensive patient with a tentative diagnosis of mild 
COPD and no symptomology, was switched from timolol maleate to latanoprost. He 
subsequently developed a bilateral hand tremor. Further exploration determined that the 
systemic absorption of the topical beta-blocker was masking an underlying essential tremor. Due 
to the patient's successful non-symptomatic history with topical timolol and the uncertainty of 
the COPD diagnosis, the beta-blocker was reinstated and the tremor resolved. The classification, 
differential diagnosis, and treatment of essential tremor is discussed as well as the mechanism of 
action and relative contraindications of timolol maleate and latanoprost. 
CASE REPORT: 
A seventy-three year old white male with a history of ocular hypertension presented for a 
routine six-month intraocular pressure check. lOP measurements before treatment were not 
known, but intraocular pressures had been well controlled with Timoptic 0.5% bid OU during the 
four years this patient had been followed. Hypertension, which was well controlled with 
nifedipine and a diuretic, was the only significant systemic condition. At the time of this visit, 
no new visual or systemic changes were noted, except the patient reported a new possible 
diagnosis of mild COPD. It was noted that the patient had no recorded history of lung problems 
during past eye exams and the medical chart was not available to confirm the diagnosis of 
COPD. 
Corrected acuities with habitual lenses were 20/15 O.D. and 20/20-2 O.S. Extraocular 
muscles were full without restrictions and pupils were equal, round, and reactive to light without 
an afferent pupillary defect. Slit lamp exam was unremarkable with deep, non-occludable 
anterior chambers. Goldmann applanation tonometry revealed lOPs of 20 mmHg O.D. and O.S. 
Humphrey 30-2 visual fields were full O.U. The patient was instructed to continue the Timoptic 
0.5% bid O.U. and return to clinic in three weeks for a fundus exam through a dilated pupil and 
medical chart review to evaluate the questionable history of COPD. 
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A review of the patient's medical chart at the next visit confirmed a tentative diagnosis of 
mild COPD, although the patient had no complaints of shortness of breath. The diagnosis was 
based on changes seen in serial chest X-rays, which had been ordered to follow an ill-defined 
opacity in the lungs thought to be secondary to pneumonia. Entrance acuities, EOMs, pupils, 
and anterior segment were similar to the previous exam. lOPs were 19 and 21 mmHg, O.D. and 
O.S. respectively. Fundus evaluation through a dilated pupil revealed cup to disc ratios of .3/.3 
O.D. and .2/.2 OS with healthy rims. Scattered pinpoint drusen and mild RPE changes were 
noted near the macular region O.U. The periphery was intact with no retinal holes or tears. 
Because of the tentative diagnosis of mild COPD, the patient was instructed to discontinue the 
Timoptic 0.5% bid and begin a two-month trial with latanoprost 0.005% qhs O.U. Lacrimal 
occlusion and eyelid closure were reviewed with the patient as well as the possible side effects of 
iris color change due to the use of latanoprost 0.005%. 
Five days after the discontinuation of the topical Timolol, the patient presented to the 
emergency room with a recent onset of bilateral hand tremors. The tremors, which were limited 
to his hands, were first noted the previous morning as he tried to eat his cereal. Emergency room 
evaluation revealed intact cranial nerves and normal motor and cerebellar function. The patient 
noted no headaches or visual changes and was alert and oriented. On testing, the tremors were 
noted to occur when the hands were outstretched, and not when the hands were at rest. History 
revealed that the only change within the last week was the discontinuation of the timolol maleate 
and institution of latanoprost. At this point, the eye clinic was notified and the patient was 
cooperatively diagnosed with essential tremor, which had previously been masked by the topical 
beta-blocker. The patient was instructed to discontinue the latanoprost and reinstate the 
Timoptic 0.5% bid O.U. with lacrimal occlusion and eyelid closure for a trial period. This was 
done due to the patient's successful non-symptomatic history with topical timolol, the 
questionable nature of the COPD diagnosis, and the possible positive systemic side effect of 
timolol in blocking the essential tremor. The patient was also asked to return to clinic in three 
days for evaluation and report immediately if shortness of breath developed 
At the three-day follow-up the tremors were almost completely resolved and lOPs were 
measured at 18 mmHg O.U. with Goldmann applanation tonometry. The patient denied 
symptoms of shortness of breath. At this time, he also mentioned that his daily blood pressure 
checks had indicated an increase in BP during the five days he was not using the Timoptic. The 
patient was instructed to continue with the Timoptic and return to clinic in one month. At the 
one-month follow-up the ocular and systemic findings were similar. At the request of the patient 
and in consultation with the primary care physician, it was decided to continue the Timoptic 
0.5% but to decrease the dosage to once daily in the morning. The possibility of increased 
tremors with the lower dosage was discussed with the patient, he was instructed to return to 
clinic in three months for review and intraocular pressure check, or immediately if ocular 
changes or shortness of breath were noted. 
DISCUSSION: 
The goal of glaucoma therapy is to reduce the intraocular pressure, therefore preventing 
damage to the optic nerve and resultant loss of vision. Timolol maleate (Timoptic, Merck), has 
accounted for 60-70% of glaucoma prescriptions in the U.S. in past years and continues to be a 
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treatment of first choice. Its method of action is to reduce the rate of aqueous humor production 
by non-selectively blocking the beta adrenoreceptors in the ciliary body, hence lowering the 
intraocular pressure an average of 27%. 1•2 Local adverse affects have included discomfort upon 
instillation, increased conjunctival hyperemia, superficial punctate keratopathy, and decreased 
corneal sensitivity. When first introduced to the market, the only labeled systemic side effect 
was a slight reduction in resting heart rate. Within two years, reports received by the United 
States Food and Drug Administration and the National Registry of Drug-Induced Ocular Side 
Effects had documented cardiac, pulmonary, and central nervous system effects.u·4 
As a result of the newly reported side effects, studies were done to link the symptoms of 
systemic beta blockade with topical administration of a beta-blocker such as timolol maleate. 
The results proved that approximately 80% of a topical eye drop is systemically absorbed 
directly into the bloodstream via the conjunctival epithelium, nasolacrimal duct, and nasal 
mucosa. Systemic levels can be quite high with topical administration because topical drops do 
not undergo first pass metabolism by the liver. In contrast, 40-70% of a dose of oral propranolol 
will undergo first-pass hepatic metabolism before entering systemic circulation. Plasma levels 
achieved from topical timolol can cause the same CNS, cardiac, and pulmonary side effects as 
systemic timolol or propranolol. Detectable blood plasma levels can be found as early as thirty 
minutes following topical beta blocker instillation4•5•6·7 
The high degree of lipid solubility innate to timolol enables it to more easily penetrate the 
plasma cerebrospinal fluid barrier and ultimately produce CNS effects such as lethargy, 
confusion, depression, anxiety, weakness, sleep disturbance, and sexual dysfunction. It is very 
common for patients to fail to link their symptomology to the use of topical timolol until after 
discontinuation of the medication. For this reason, the prescribing doctor should probe for the 
presence of possible CNS side effects during regular patient office visits.1•8•9·10 
Less common are the cardiac and pulmonary side effects associated with topical beta 
blocker-induced systemic beta blockade. Cardiac blockade involves mainly beta-1 
adrenoreceptors and causes decreased cardiac rate, decreased myocardial contractility, and 
prolongation of atrioventricular conduction. This will result in reduced resting and exercise-
induced maximum heart rate and a lower blood pressure. Episodes of syncope, bradycardia and 
dyspnea while using topical timolol, have been documented.7 Parasympathetic blockade ofbeta-
2 receptors primarily affects the pulmonary system and can result in impaired lung function that 
is relatively asymptomatic or bronchospasm and bronchial asthma attacks. Pre-existing 
bronchospastic disease may have increased risk for bradyarrhythmia, hypotension, syncope, and 
bronchospasm associated with systemic beta blockade. Patients with a history of asthmatic 
bronchitis have been found to have a 25% decrease in forced expiratory volume less than fifteen 
minutes after topical instillation. Lung function tests are recommended before and during 
treatment with topical ocular timolol in patients at risk. 11 Topical timolol use is contraindicated 
in patients with a past history of bronchial asthma, severe chronic pulmonary disease, congestive 
heart failure, preexisting cardiac disease, sinus bradycardia, and high grade heart block. Patients, 
especially those at risk, should be closely monitored during the first week of initial treatment 
because data supports that this is the critical period when most side effects will become 
manifest. 1.2.4.B.9.1i 
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Other documented systemic effects of topical timolol are dermatologic rashes and 
alopecia. Beta blockade caused by beta-blockers can also mask the diabetic "shakes" that 
normally serve to warn a patient of an impending hypoglycemic attack. Potential drug side 
effects associated with concurrent use of topical beta-blockers can be particularly serious with 
verapamil, diltiazem, amiodarone, and digitalis. 12 
Eyelid closure and punctal occlusion have been found to both increase ocular exposure 
time which increases drug efficacy, and decrease systemic absorption through the nasolacrimal 
system. Although there is documentation of great variation between amount and method of 
systemic absorption among topical timolol patients, even a small decrease in the absorption 
could have a great effect on the level of systemic beta-blockade. Systemic absorption of topical 
medications may be reduced by up to 50% with the practice of punctal occlusion. Gentle eye 
closure while sitting for three minutes has been shown to reduce systemic absorption of timolol 
by 66% and may be safer and easier than punctal occlusion. Both punctal occlusion and eyelid 
closure have been shown to be effective in reducing absorption but significant beta blockade can 
occur with even relatively low plasma levels. 
Comparison of morning versus evening instillation of 0.5% timolol reveals no 
statistically significant difference in lOP lowering effect. A similar result was found in 
comparing once daily administration of 0.25% timolol with the same dosage of 0.5% timolol. 
This indicates that a lower concentration of timolol maleate in a once daily dosage is sufficient 
for maximum lOP reduction. Potentially, once-daily dosing could increase compliance and 
decrease the likelihood of systemic blockade-induced side effects.6•9•13•14 
In order to reduce the incidence of systemic complications secondary to topical beta-
blocker instillation, there are several steps that should be followed. First, a complete patient 
history to determine the presence of cardiac, pulmonary or drug interaction contraindications 
should be performed. The patient's pulse should be evaluated and reconsideration of use of a 
beta-blocker should occur if the heart rate is irregular or below sixty beats per minute. 
Instruction regarding dosage amount and time of day, eyelid closure and punctal occlusion, and 
the possibility of systemic side effects should be given. The family physician should be 
informed of the start of a topical beta-blocker and questioned about any known contraindications 
or potential drug interactions. The patient should be monitored carefully during the first week of 
treatment and educated to return to the clinic immediately if systemic side effects are 
experienced. 11 ' 13 
Because of the contraindication of pulmonary problems for timolol maleate, we switched 
our patient to latanoprost. Latanoprost 0.005% solution (Xalatan, Pharmacia & Upjohn) is a 
member of a new class of ocular hypotensive agents known as prostaglandin analogs. 
Prostaglandins are a group of naturally occurring fatty acids that are found in nearly every tissue 
in the body. The mechanism of action to reduce lOP appears to result from enhancement of 
uveoscleral outflow. Latanoprost is highly lipophilic and easily permeates into the cornea where 
it is hydrolyzed into a hydrophilic free acid, which diffuses into the aqueous. The most 
commonly reported ocular side effects include: blurred vision, burning and stinging, conjunctival 
hyperemia, foreign-body sensation, punctate epithelial keratopathy, and increased iris 
pigmentation. Latanoprost appears to increase the number of melanosomes within the 
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melanocytes which gradually produces an iris color change from lighter to dark. This is 
especially common in patients with mixed color irides. Although it may take months to years to 
become noticeable, the color change in most cases is permanent and therefore, patients should be 
forewarned. Studies of systemic absorption indicate that it is quickly metabolized and excreted 
upon entering the circulation. Latanoprost has no cardiopulmonary contraindications, does not 
have statistically significant effects on heart rate or blood pressure, and is well tolerated in 
asthmatic patients. Therefore, Latanoprost is indicated for patients with open-angle glaucoma 
and ocular hypertension with previous intolerance or poor response to other lOP-reducing 
medications. 
Once-daily dosing of latanoprost reduces lOP 27% to 35%, and maintains uniform 
diurnal and circadian lOP reduction. Evening administration is the most effective. When 
compared to twice-daily administration of timolol maleate 0.5%, latanoprost 0.005% has been 
shown to be as effective in lowering lOP in patients with primary open angle glaucoma and 
ocular hypertension. Latanoprost has been shown to maintain efficacy for up to twelve months 
and can be used in conjunction with other antiglaucoma agents to further lower lOP. Study 
results show that once-daily latanoprost in the evening can be safely substituted for timolol 
maleate 0.5% bid with some enhancement of lOP lowering effect. 15 
Tremor is an involuntary repetitive movement of the extremities or head that is produced 
by alternating contraction of opposing muscles. Classification of tremor is by area of the body 
affected, frequency of oscillation, amplitude, and most importantly, the body position that 
maximizes the tremor.16 Postural, or action tremor occurs while the body part is maintaining 
itself against the force of gravity, such as extending one's arms out in front of the body or lifting 
an eating utensil. A tremor that occurs while the affected body part is at rest is termed a resting 
tremor. Tremor with goal-directed movements is referred to as a kinetic or intentional tremor. 
Both resting tremor, found in Parkinson's disease, and intentional tremor are characteristic of 
central nervous system disorders of the cerebellar or extrapyramidal systems. 16•17·18 Action 
tremors have multiple causes including: normal physiologic tremor which is exacerbated by 
fatigue and anxiety; metabolic tremor associated with drug withdrawal, liver disease, and metal 
poisoning; orthostatic tremor that occurs only when standing; and drug-induced tremor 
secondary to amphetamines, steroids, caffeine, antipsychotics and lithium. Benign essential 
tremor, as diagnosed in this case, is another category of action tremor.18 
Essential tremor (ET) is the most common of the movement disorders. Although 
sometimes it can be misdiagnosed as Parkinson's disease, it is considered "benign". ET does 
not affect the lifespan but can cause severe disability and social embarrassment as patients with 
ET often have difficulty dressing themselves, writing, or handling utensils. United States 
epidemiological studies have estimated that there are over five million cases of ET with no 
predilection to gender or race noted. Peak incidence occurs at both the second and sixth decades 
and once started will last throughout life. Essential tremor most commonly affects the hands and 
fingers initially. Progression to other body parts and an increase in severity can occur, with head 
involvement eventually developing in 60% and voice tremor in 24% of these patients. 
Progression is typically slow and may develop over one to two decades before the patient seeks 
medical intervention. Anxiety, fatigue, and temperature changes can exacerbate the tremor, 
which disappears completely with sleep.16•19•20 A fine, low amplitude tremor is the only 
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symptom in essential tremor. 18'19 Post mortem examination is rare due to the benign status of the 
disorder, but the six reported exams have resulted in no obvious pathology in the cerebellar or 
extrapyramidal systems. There was also no abnormal muscle spindle feedback or change in 
sensitivity of the peripheral beta receptors. Studies with positron emission tomography have 
shown increased cerebral blood flow in subjects with ET, indicating a potential central 
mechanism. Another theory suggests essential tremor may be an exaggeration of normal 
physiologic tremor, although this evidence has been challenged. 16•19 Both central and peripheral 
etiologies have been studied but currently the exact pathophysiology of essential tremor remains 
unknown. 
There is no standard classification system for essential tremor within the current literature 
but classification by age and history is commonly used. Individuals with essential tremor have a 
50-75% chance of a positive family history for the disorder and the condition is believed to be 
inherited as an autosomal dominant trait with variable penetrance. Familial essential tremor is 
used for patients with a positive family history and senile essential tremor is used in individuals 
over the age of 65 with no family history. A "sporadic" form also occurs before the age of 65 
with no family history. 
A different classification system divides ET into four subtypes. Type I is a form of 
benign exaggerated physiologic tremor that has a frequency of 6-12Hz. Benign pathological 
essential tremor, which has a frequency of 5-7 Hz, is the second type. It contains the familial 
and senile forms of the disorder. The tremor in this subtype can be minimized through treatment 
with beta blockers and alcohol. Severe pathologic essential tremor, which is Type III, is very 
disabling and can include the head and legs. It is not decreased with alcohol or beta-blockers. 
Type IV, known as symptomatic essential tremor, includes tremors associated with other 
1 . al d' . 1619 neuro og1c· con 1t1ons. ' 
The standard treatment for benign essential tremor is the use of propranolol, a systemic 
non-selective beta-blocker, which can reduce the tremor to tolerable levels. Results are 
inconsistent and dosages range from 60-320 mg/day as necessary and as tolerated.16•17•18•21 
Comparative studies have shown that blockade of peripheral beta-2 receptors is the most likely 
mechanism of reducing the tremor, although central beta-1 effects have not been excluded. The 
site of action is not fully understood as propranolol is highly lipid soluble and easily penetrates 
the CNS, therefore blocking both beta-1 and beta-2 adrenoreceptors.19 As with topical beta-
blockers, the presence of chronic obstructive pulmonary disease, asthma, or congestive heart 
failure contraindicates the use of propranolol. The cardioselective (B 1) beta-blocker Metoprolol 
has been used as an alternative in patients suffering from bronchospasm. 16·18·19•21 
Less common treatments have also been used in cases of essential tremor. Alcohol has 
been found to reduce an action tremor but is not a treatment of choice for long term use?1 
Primidone, an anticonvulsant, was recently found to be at least as equally effective as 
propranolol but causes serious acute side effects of vertigo, nausea, ataxia and confusion in 30% 
of the patients. The effects do typically subside after one to four days of use and the patient is 
encouraged to "wait it out." The benzodiazapenes Clonazepam and Alprazolam have shown 
promise in some studies but also induce sedation. A new treatment using Botox A reduced 
tremor in 70% of patients in recent studies and warrants further investigation. Surgery, which 
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involves a stereotaxic thalamotomy of the ventral intermediate nucleus, is an option in severe 
cases or in patients with poor response to medicinal therapies, and is considered effective and 
long term. New techniques involve surgical implantation of a device connected to a pulse 
generator that chronically stimulates the ventral intermediate thalamic nucleus. This procedure 
is considered to be superior to thalamotomy and results show improvement in 90% of patients 
with complete relief in some cases. In cases when the tremor is not disabling to the patient, the 
treatment is simply reassurance that the disorder is not serious or life threatening. 16•19 
Differential diagnosis of benign essential tremor from other types and causes of tremor is 
usually by history, age, and associated signs and symptoms. Parkinson's Disease, a common 
misdiagnosis for sufferers of ET, is characterized by a coarse, resting tremor of 4-8 Hz. The 
tremor disappears with movement and sleep. A Parkinson's patient is usually older and has 
associated signs of cogwheel rigidity, bradykinesia, and micrographia. Handwriting is 
considered a good differential between the two disorders, as an essential tremor patient's 
handwriting is usually large and tremulous. 16•17•19 
Intentional tremor, caused by a cerebellar disorder, can be elicited with a heel-to-shin test 
in which the patient will develop the tremor during these intentional movements. Cerebellar 
disorders will also have accompanying signs of speech disorders, dysmetria or inability to judge 
movement, and asynergy or lack of coordination. Hepatolenticular degeneration, also known as 
Wilson's disease, has a characteristic rapidly violent flapping of the hands and arms and will also 
display associated ocular and physical signs. A fine, rapid tremor of the face, tongue, and hands 
is possible in the dementia paralytica caused by neurosyphillis. This tremor is secondary to 
damage of the frontal lobe connection to the brainstem. Tremor caused by multiple sclerosis 
occurs with the movement of the limbs, disappears at rest, and will also have associated 
symptoms. Hyperthyroidism causes a fine, regular and rapid tremor that is usually only in the 
fmgers with accompanying ocular and physical signs. Toxic causes of tremor include 
alcoholism, drug poisoning, and cocaine or morphine use and will be evidenced by history. 
Psychologically, tremor can be caused by chronic or acute anxiety and has a variable 
presentation. 17 
Conclusion: 
Topical beta-blockers are certainly contraindicated in patients with certain cardiac or 
pulmonary conditions. New diagnosis of these conditions may cause an eyecare practitioner to 
switch their patient from a beta-blocker to a topical medication with less systemic side effects 
like latanoprost. Even though this is indicated, it can have surprising results such as the 
unmasking of this patient's essential tremor. 
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